News

As stated in article published in the clinical journal Neurobiology of Aging, a team of researchers has discovered that elevated levels of certain types of lipids in the brain could be an early presentation of Parkinson’s disease.

The 7-year data showed the median seizure frequency reduction of 75% in those with drug-resistant epilepsy with partial-onset seizures receiving DBS therapy.

This morning, Acceleron Pharma announced that the US FDA has granted Fast Track designation to ACE-083 for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD).

This morning, it was announced that the U.S. FDA has approved dabrafenib (Tafinlar) in combination with trametinib (Mekinist) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutation.

Modeling predicts cost-effective approach to HIV drug resistance in low-resource, highly afflicted sub-Saharan Africa.

Positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase 3 clinical program of fostamatinib disodium hexahydrate (Tavalisse) were published in the American Journal of Hematology this week.

At the Clinical immunology Society Annual Meeting in Toronto on April 27-28, Prometic presented data from its pivotal Intravenous Immunoglobin (IVIG) Phase 3 clinical trial.

Two additional implants are added to the current spine labeling.

The filing is supported by data from MERIT-1 which showed great improvements in pulmonary vascular resistance and 6-minute walk distance versus ongoing background therapy.

This is the first drug in a new class of antiretroviral medications that does not require daily dosing and can greatly provide benefit to patients who have run out of HIV treatment options.

The U.S. FDA has accepted for priority review the Biologics License Application for cemiplimab (REGN2810), an investigational anti-PD-1 monoclonal antibody for patients with metastatic CSCC.

The solution to lower elevated intraocular pressure is approved 2 months ahead of the scheduled PDFUA date.

This morning, Capricor Therapeutics, Inc. announced that the HOPE-2 clinical trial has been initiated at UC Davis Medical Center in Sacramento, CA.

The investigational drug programs represent a high unmet medical need as there are currently no approved therapeutics targeting the impairment caused by the mutations.

At the NLA Scientific Sessions, Akcea Therapeutics presented a poster with data from 2 different studies, each of which exhibited a significant reduction of triglycerides in patients with FCS when administered volanesorsen.

The prevalence of ASD among 8-year-old children has increased 0.2%, including increases in the black and Hispanic communities according to recent CDC data.

A daily, 6-month ATT regimen in HIV-positive patients with TB receiving concomitant ART proved superior to an intermittent regimen in terms of efficacy and prevention of ARR.

At the NLA Scientific Sessions in Las Vegas, NV this weekend, Akcea Therapeutics will present clinical data on volanesorsen and FCS.

This morning, biotechnological company Saniona announced that it has obtained approval to initiate the second part of its Phase 2a trial for Tesomet in adolescents with Prader-Willi syndrome (PWS).

This morning, top-line data from a confirmatory Phase 2 study of NP001 in ALS were reported, and showed that the trial did not meet its primary or secondary endpoints.

Dystrophic epidermolysis bullosa treatment receives IND clearance.

The American Academy of Family Physicians is seeking to fight physician burnout with newly announced resources.

A favorable overall response to treatment was comparable between the IMI/REL (71.4%) and the colistin plus IMI (70%) arms.

How an Australian anesthetist and English midwife student convinced providers around the world to be open about their names.

These findings provide health care decision-makers with novel information about the allocation of scarce resources relating to Clostridium difficile.

The agency warns that the seizure and bipolar disorder medication can cause hemophagocytic lymphohistiocytosis, a rare but very serious immune system reaction.

Data from Type 1 spinal muscular atrophy (SMA) treatment suggests efficacy and tolerability.

CLN2 disease treatment reduces rate of clinical decline in children.

IONIS-HTT data shows link between reduction in Huntingtin protein and clinical improvement.

FLT3mut+ Relapsed/Refractory AML treatment submits New Drug Application.